

Jane K Sosabowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1270437/publications.pdf>

Version: 2024-02-01

46
papers

1,671
citations

236925

25
h-index

276875

41
g-index

47
all docs

47
docs citations

47
times ranked

2898
citing authors

#	ARTICLE	IF	CITATIONS
1	MCTR3 reprograms arthritic monocytes to upregulate Arginase-1 and exert pro-resolving and tissue-protective functions in experimental arthritis. <i>EBioMedicine</i> , 2022, 79, 103974.	6.1	8
2	Bioconjugated technetium carbonyls by transmetalation reaction with zinc derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 37, 127840.	2.2	2
3	New Bioconjugated Technetium and Rhenium Folates Synthesized by Transmetalation Reaction with Zinc Derivatives. <i>Molecules</i> , 2021, 26, 2373.	3.8	2
4	¹⁸ F-Trifluoromethanesulfinate Enables Direct C-H ¹⁸ F-Trifluoromethylation of Native Aromatic Residues in Peptides. <i>Journal of the American Chemical Society</i> , 2020, 142, 1180-1185.	13.7	61
5	Neutron Activated ¹⁵³ Sm Sealed in Carbon Nanocapsules for <i>in Vivo</i> Imaging and Tumor Radiotherapy. <i>ACS Nano</i> , 2020, 14, 129-141.	14.6	37
6	Cancer associated fibroblast FAK regulates malignant cell metabolism. <i>Nature Communications</i> , 2020, 11, 1290.	12.8	95
7	Systemic delivery and SPECT/CT <i>in vivo</i> imaging of ¹²⁵ I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. <i>Scientific Reports</i> , 2019, 9, 12840.	3.3	8
8	Membrane Radiolabelling of Exosomes for Comparative Biodistribution Analysis in Immunocompetent and Immunodeficient Mice - A Novel and Universal Approach. <i>Theranostics</i> , 2019, 9, 1666-1682.	10.0	94
9	Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89. <i>Biomolecules</i> , 2019, 9, 91.	4.0	11
10	New Developments in Imaging Cell-Based Therapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 730-735.	5.0	18
11	DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1010-1016.	5.0	36
12	AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting. <i>Oncotarget</i> , 2019, 10, 4276-4289.	1.8	14
13	Radiolabeled Antibodies Against M ₄ Muscarinic Acetylcholine Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1234-1242.	5.0	15
14	Anesthesia and Monitoring of Animals During MRI Studies. <i>Methods in Molecular Biology</i> , 2018, 1718, 423-439.	0.9	5
15	Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells. <i>Nature Communications</i> , 2018, 9, 1081.	12.8	59
16	Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting. <i>Theranostics</i> , 2018, 8, 2896-2908.	10.0	27
17	Functionalised Carbon Nanotubes Enhance Brain Delivery of Amyloid-Targeting Pittsburgh Compound B (PiB)-Derived Ligands. <i>Nanotheranostics</i> , 2018, 2, 168-183.	5.2	48
18	High-throughput high-volume nuclear imaging for preclinical <i>in vivo</i> compound screening. <i>EJNMMI Research</i> , 2017, 7, 33.	2.5	2

#	ARTICLE	IF	CITATIONS
19	Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo. <i>Biomaterials</i> , 2017, 120, 126-138.	11.4	21
20	Novel Hyaluronic Acid Conjugates for Dual Nuclear Imaging and Therapy in CD44-Expressing Tumors in Mice <i>In Vivo</i> . <i>Nanotheranostics</i> , 2017, 1, 59-79.	5.2	42
21	Triple-Modal Imaging of Magnetically-Targeted Nanocapsules in Solid Tumours <i>In Vivo</i> . <i>Theranostics</i> , 2016, 6, 342-356.	10.0	55
22	Pre-clinical quantitative imaging and mouse-specific dosimetry for 111In-labelled radiotracers. <i>EJNMMI Research</i> , 2016, 6, 85.	2.5	2
23	The Shortening of MWNT-SPION Hybrids by Steam Treatment Improves Their Magnetic Resonance Imaging Properties In Vitro and In Vivo. <i>Small</i> , 2016, 12, 2893-2905.	10.0	21
24	Translocation of LRP1 targeted carbon nanotubes of different diameters across the blood-brain barrier in vitro and in vivo. <i>Journal of Controlled Release</i> , 2016, 225, 217-229.	9.9	111
25	Kinetics of functionalised carbon nanotube distribution in mouse brain after systemic injection: Spatial to ultra-structural analyses. <i>Journal of Controlled Release</i> , 2016, 224, 22-32.	9.9	48
26	Pharmacokinetic Characteristics, Pharmacodynamic Effect and In Vivo Antiviral Efficacy of Liver-Targeted Interferon Alpha. <i>PLoS ONE</i> , 2015, 10, e0117847.	2.5	5
27	Evaluation and comparison of a new DOTA and DTPA - bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models. <i>Applied Radiation and Isotopes</i> , 2015, 96, 91-101.	1.5	13
28	Contrast Agents: Magnetically Decorated Multiwalled Carbon Nanotubes as Dual MRI and SPECT Contrast Agents (<i>Adv. Funct. Mater.</i> 13/2014). <i>Advanced Functional Materials</i> , 2014, 24, 1879-1879.	14.9	1
29	Adoptive Immunotherapy of Epithelial Ovarian Cancer with $\gamma\delta$ T Cells, Potentiated by Liposomal Alendronic Acid. <i>Journal of Immunology</i> , 2014, 193, 5557-5566.	0.8	43
30	The relationship between the diameter of chemically-functionalized multi-walled carbon nanotubes and their organ biodistribution profiles in vivo. <i>Biomaterials</i> , 2014, 35, 9517-9528.	11.4	57
31	Magnetically Decorated Multiwalled Carbon Nanotubes as Dual MRI and SPECT Contrast Agents. <i>Advanced Functional Materials</i> , 2014, 24, 1880-1894.	14.9	72
32	Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles. <i>International Journal of Nanomedicine</i> , 2013, 8, 4659.	6.7	43
33	Liver-Targeting of Interferon-Alpha with Tissue-Specific Domain Antibodies. <i>PLoS ONE</i> , 2013, 8, e57263.	2.5	20
34	Preclinical Evaluation of Radiolabeled DOTA-Derivatized Cyclic Minigastrin Analogs for Targeting Cholecystokinin Receptor Expressing Malignancies. <i>Molecular Imaging and Biology</i> , 2012, 14, 366-375.	2.6	27
35	Radiolabelled peptides for oncological diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 78-92.	6.4	71
36	Comparative biodistribution of 12 111In-labelled gastrin/CCK2 receptor-targeting peptides. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1410-1416.	6.4	88

#	ARTICLE	IF	CITATIONS
37	Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹ In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1417-1425.	6.4	63
38	Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1426-1435.	6.4	70
39	Radiopeptide internalisation and externalisation assays: Cell viability and radioligand integrity. <i>Applied Radiation and Isotopes</i> , 2011, 69, 68-74.	1.5	5
40	Quantitative Accuracy of Low-Count SPECT Imaging in Phantom and In Vivo Mouse Studies. <i>International Journal of Molecular Imaging</i> , 2011, 2011, 1-8.	1.3	23
41	Insertion of a Lysosomal Enzyme Cleavage Site into the Sequence of a Radiolabeled Neuropeptide Influences Cell Trafficking In Vitro and In Vivo. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 89-95.	1.0	17
42	Targeting of CCK-2 Receptor-Expressing Tumors Using a Radiolabeled Divalent Gastrin Peptide. <i>Journal of Nuclear Medicine</i> , 2009, 50, 2082-2089.	5.0	41
43	Selection of Radiolabeled Gastrin Analogs for Peptide Receptor-Targeted Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2007, 48, 615-622.	5.0	64
44	Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study. <i>European Journal of Pharmaceutical Sciences</i> , 2007, 31, 102-111.	4.0	12
45	Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes. <i>Nature Protocols</i> , 2006, 1, 972-976.	12.0	54
46	Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 638-646.	6.4	40